Pulmonic Valve REplacement Multi-discIpline EMEA Registry

NCT ID: NCT01356108

Last Updated: 2018-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

127 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2017-12-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry is to retrospectively and prospectively obtain clinical data in consecutively treated patients, in order to demonstrate that the commercially available Edwards SAPIEN Valve with the RF3 delivery system is a safe and effective treatment for patients with pulmonary regurgitation or stenosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Consecutive patient data should be collected at discharge, 6 months, 12 months and 2-5 years post-implant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Regurgitation Pulmonary Insufficiency Pulmonary Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)

The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Symptomatic with a regurgitant or stenotic pulmonary valved conduit.

Exclusion Criteria

* Angiographic evidence of coronary artery compression.
* RV-PA pulmonary conduit size that is either too large or too small to accommodate the SAPIEN THV.
* Thrombus or intracardiac mass in the right atrium, right ventricle, and/or pulmonic valve.
* Severe coagulation problems and/or unable to tolerate anticoagulation/antiplatelet therapy.
* Active bacterial endocarditis or other active infections.
* Illeofemoral venous stenosis that may prevent the placement of the introducer sheath and/or central venous vascular tortuosities that may prevent advancement of the delivery system to the heart or into the pulmonary artery.
* Presence of any prosthetic valve in the tricuspid position.
* Unstable coronary artery disease-related angina.
* Placement of the SAPIEN THV in pregnant females.
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Ewert, MD

Role: PRINCIPAL_INVESTIGATOR

Deutsches Herzzentrum München

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Leuven

Leuven, , Belgium

Site Status

Herz und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

German Heart Institute Berlin

Berlin, , Germany

Site Status

Deutsches Herzzentrum München

München, , Germany

Site Status

Universitätsklinikum Münster

Münster, , Germany

Site Status

Mater Misericordiae University Hospital

Dublin, , Ireland

Site Status

Schneider Children's Medical Center of Israel

Petach Tikvah, , Israel

Site Status

Ospedale Bambino Gesù

Rome, , Italy

Site Status

Policlinico San Donato

San Donato Milanese, , Italy

Site Status

The Cardinal Stefan Wyszyński Institute of Cardiology

Warsaw, , Poland

Site Status

King Faisal Specialist Hospital & Research Centre

Riyadh, , Saudi Arabia

Site Status

Prince Sultan Cardiac Centre

Riyadh, , Saudi Arabia

Site Status

Mehmet Akif Ersoy Thoracic & Cardiovascular Surgery

Istanbul, , Turkey (Türkiye)

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

The Heart Hospital

London, , United Kingdom

Site Status

Manchester Royal Infirmary

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Ireland Israel Italy Poland Saudi Arabia Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PARTNER 3 Trial - Mitral Valve in Valve
NCT03193801 ACTIVE_NOT_RECRUITING NA
ALTERRA Post-Approval Study
NCT05378386 ACTIVE_NOT_RECRUITING
The ENCIRCLE Trial
NCT04153292 RECRUITING NA